Use of EP2 selective receptor agonists in medical treatment

A technology of receptor agonists and limbs, applied in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve problems such as reduced physical activity

Inactive Publication Date: 2006-11-08
PFIZER PRODS ETAT DE CONNECTICUT
View PDF55 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are serious side effects associated with PGE2 such as diarrhea, gastrointestinal bleeding, decreased food intake, dehydration, w...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of EP2 selective receptor agonists in medical treatment
  • Use of EP2 selective receptor agonists in medical treatment
  • Use of EP2 selective receptor agonists in medical treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0401] To obtain the dosing forms in strengths of 5 and 50 mgA / ml, the following combinations A) and B) of lyophilized powder and polymeric syringes were used respectively:

[0402] A) 5 mgA / ml (after reconstitution) of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid Sodium preparations:

[0403] Drug Syringe A: lyophilized powder containing 4 mg of A sodium salt in a 1.25 ml unmarked male syringe; and

[0404] Vehicle Syringe B: Contains 0.8 ml of 50% RG502H / 50% NMP solution in a 1.25 ml ungraduated female syringe.

[0405] B) 50 mgA / ml (after reconstitution) of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid Sodium preparations:

[0406] Drug Syringe A: lyophilized powder containing 40 mg A sodium salt in 1.25 ml ungraduated male (crude) B-D syringes; and

[0407] Vehicle Syringe B: Contains 0.8 ml of 50% RG502H / 50% NMP solution in a 1.25 ml ungraduated female (thin) syringe.

[0408] MgA refers t...

Embodiment 1

[0412] 50% RG502H / 50% NMP with 5 mgA / ml of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)- Sodium acetate, mix A / B (autoclaved polymer solution, lyophilized compound)

Embodiment 2

[0414] 50% RG502H / 50% NMP with 10 mgA / ml of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)- Sodium acetate, mix A / B (irradiated polymer solution, lyophilized compound)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Description

field of invention [0001] The present invention involves the use of EP 2 Selective receptor agonists for treatment of pulmonary hypertension, promotion of joint fusion, promotion of tendon and ligament repair, reduction of secondary fractures, treatment of avascular necrosis, promotion of cartilage repair, promotion of bone healing after limb transplantation, promotion of liver regeneration, promotion of Methods of healing wounds, reducing the incidence of gastric ulcers, treating high blood pressure, promoting tooth enamel or nail or toenail growth, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease. Background of the invention [0002] Prostaglandin receptor ligand compounds are known to be useful in the treatment of various diseases such as osteoporosis. Various natural prostaglandins such as PGE, PGD and PDF are involved in bone metabolism. PGE2 has been reported to stimulate bone formation, incr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/185A61K31/415A61K31/433A61P1/04A61P9/02A61P19/00A61P27/06
CPCA61K31/185A61K31/415A61K31/433A61P1/02A61P1/04A61P1/16A61P9/00A61P9/02A61P9/12A61P11/00A61P17/02A61P19/00A61P19/02A61P27/02A61P27/06A61P43/00
Inventor A·A·康斯坦P·R·科沙里D·B·麦克林V·M·帕拉尔卡D·C·罗曼D·D·汤普森T·M·莱特
Owner PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap